Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A 78-year-old man visited our hospital complaining of cognitive decline and gait disturbance. MRI revealed multiple nodular enhancing lesions in the brain. He was pathologically diagnosed with central nervous system-lymphomatoid granulomatosis (CNS-LYG) by brain biopsy. Brain PET examinations using 18F-fluorothymidine (FLT) PET and 11C-methionine (MET) PET were performed. Strong accumulation in the lesions was observed with 18F-FLT PET. After treatment, the accumulation of lesions disappeared, and accumulation was observed again at the time of recurrence. In contrast, 11C-MET PET showed unclear accumulation in the lesions both before therapy and at recurrence. 18F-FLT uptake was likely reflecting the degree of cell infiltration and the disrupted blood-brain barrier. 18F-FLT PET might be a useful tool for evaluating the therapeutic response and recurrence of CNS-LYG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005953 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interactions Among Tumor Subtype, PPARγ Expression, and Adipose Proliferation Shape Outcomes in Breast Cancer.
medRxiv
July 2025
Departments of Cellular & Molecular Physiology, Internal Medicine (Endocrinology), and Comparative Medicine, Yale University, New Haven, CT, United States.
Breast cancer progression is influenced by tumor subtype, metabolic environment, and patient factors, including menopausal status and BMI. In this study, we utilize publicly available data to investigate the prognostic relevance of γ gene expression, a key regulator of lipid metabolism, and its implications across different subgroups. We also examine the proliferation of adipose tissue in patients with various tumor subtypes and phenotypic cohorts.
View Article and Find Full Text PDFExploring the role of tumor to background parenchymal ratio of the [18F]FLT PET/CT measures in determining response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
BMC Cancer
July 2025
Head of Radiology Department, Faculty of Medicine, Urmia University of Medical Science, Urmia, Iran.
Objective: To investigate the potential of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography computed tomography ([18F]FLT PET/CT) in predicting locally advanced breast cancer response to neoadjuvant chemotherapy (NAC), focusing on the role of tumor to background parenchymal ratio (TBR) of the standardized uptake value (SUV) ratios.
Methods: This retrospective analysis utilized prospectively collected data from the multicenter ACRIN 6688 observational trial. It used a dataset of 90 patients from 17 centers with confirmed breast cancer who planned to receive NAC followed by surgery as part of their treatment.
[F]-FLT-PET to evaluate how the sequencing of chemotherapies impacts the efficacy of combination treatment in mouse models of triple-negative breast cancer.
Neoplasia
August 2025
Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA. Electronic address:
Introduction: Triple-negative breast cancer (TNBC) lacks targeted therapies due to an absence of biomarkers, making chemotherapy the primary treatment option for early-stage cancer. This study evaluates whether the order and sequence of combination chemotherapy-doxorubicin (DRB) and paclitaxel (PTX)-affects treatment efficacy in TNBC.
Methods: In vitro and in vivo models (MDA-MB-231 human and 4T1 syngeneic mouse TNBC) were used to assess treatment efficacy across three groups: saline control, DRB→PTX, and PTX→DRB.
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?
Clin Nucl Med
August 2025
Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Background: 18 F-FLT PET/CT visualizes cellular proliferation and may correlate more directly with tumor aggressiveness and treatment response than 18 F-FDG PET/CT in melanoma patients treated with BRAF/MEK inhibitors. We aimed to assess whether 18 F-FLT PET/CT can predict early resistance to BRAF/MEK inhibitors in addition to current clinical tools in patients with BRAF-mutated metastatic melanoma.
Patients And Methods: This explorative side study of the phase II multicenter REPOSIT trial included 19 patients with stage IV BRAF V600E/K-mutated cutaneous melanoma who underwent optional 18 F-FLT PET/CT.
Chronic treatment with adenosine A1 receptor antagonist promotes neurogenesis and improves outcome after cerebral ischemia.
J Cereb Blood Flow Metab
May 2025
Achucarro Basque Center for Neuroscience, Leioa, Spain.
Adenosine A1 receptors (A1ARs) are promising targets for stroke treatment, potentially due to their relatively unexplored effects on proliferation and differentiation of newborn neurons. In this study, we investigated the impact of chronic treatment with the A1ARs antagonist DPCPX on neurogenesis following MCAO in rodents, using PET with [F]FLT in rats and immunohistochemistry in mice. In addition, we assessed the therapeutic properties of DPCPX on stroke recovery with a comprehensive battery of neurological and behavioral tests.
View Article and Find Full Text PDF